CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 128 enrolled
Drug / intervention
Selective Serotonin Reuptake Inhibitor(SSRIs,Fluoxetine, paroxetine, fluvoxamine, sertraline, citalopram, escitalopram)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05588102
NCT05588102N/ACompleted

Research on Standardized Electronic Cognitive Training Technique in Early Stage of Senile Depression With Cognitive Impairment

Capital Medical University·interventional·Posted Oct 20, 2022·Updated Jul 16, 2024

In Brief

A clinical study evaluating Selective Serotonin Reuptake Inhibitor(SSRIs,Fluoxetine, paroxetine, fluvoxamine, sertraline, citalopram, escitalopram) for Geriatric Depression and Cognitive Impairment. Completed, enrolled 128 participants across 1 site.

Detailed Summary

late-life depression (LLD) is the most common mental illness in the elderly. Due to the increasing prevalence of population aging, it has become one of the important factors affecting the quality of life of the elderly. 50-70% of elderly patients with depression are accompanied by different degrees of cognitive impairment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina
Collaborators--

Timeline

N/ACompletedFinished
20222023202420252026
First PostedOct 20, 2022
Enrollment StartMay 18, 2021
Primary CompletionMay 1, 2023
Study CompletionAug 1, 2023
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 3.7 years ago

Interventions

Selective Serotonin Reuptake Inhibitor(SSRIs,Fluoxetine, paroxetine, fluvoxamine, sertraline, citalopram, escitalopram)drug

Subjects in the intervention group received SSRIs antidepressants combined with Electronic cognitive training based on mobile phone platform for 52 weeks (once a day, 60min each time)